Please assess the completion status of the following clinical trial:

Trial Title: Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, age 18 to 80 years~* Diagnosis of chronic angina due to obstructive coronary artery disease that is refractory to drug therapy and unsuitable for revascularization via coronary artery bypass graft or percutaneous coronary intervention~* Angina class II-IV based on Canadian Cardiovascular Society Classification of Angina Pectoris~* Adequate hematologic (hemoglobin ≥ 10 g/dL, absolute neutrophil count \> 1.2 × 10\^3 per μL and platelet count ≥ 75,000 per μL), hepatic (alanine aminotransferase and aspartate aminotransferase ≤ 3 x ULN; total bilirubin ≤ 2 x ULN), and renal function (glomerular filtration rate \> 29 mL/minute/1.73 m2)~* Adequate birth control if of child-bearing potential~* Must be willing and able to provide informed consent~Exclusion Criteria:~* ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI) not requiring revascularization, transmural myocardial infarction or cerebral vascular accident within the past 30 days~* New York Heart Association Function Class III or IV or left ventricular ejection fraction \< 25% within the 6 weeks prior to the screening visit~* HbA1c ≥ 8.5%, SBP \<90 or \>180 mmHg, DBP \>100 mmHg~* Other concurrent medical conditions that could jeopardize the safety of the subject or objectives of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AdVEGFXC1 at 1x10^9 vp (Type: EXPERIMENTAL): None
- AdVEGFXC1 at 1x10^10 vp (Type: EXPERIMENTAL): None
- AdVEGFXC1 at 4x10^10 vp (Type: EXPERIMENTAL): None
- AdVEGFXC1 at 1x10^11 vp (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).